Supplementary Online Content

Mezzacappa A, Lasica P-A, Gianfagna F, et al. Risk for autism spectrum disorders according to period of prenatal antidepressant exposure: a systematic review and meta-analysis. *JAMA Pediatr.* Published online April 17, 2017. doi:10.1001/jamapediatrics.2017.0124

eTable. Description of the Studies on Antidepressant Exposure During Pregnancy and ASD.

eFigure 1. Meta-analysis on ASD and AD: First-Trimester Exposure.

eFigure 2. Meta-analysis on ASD and AD: Second-Trimester Exposure.

eFigure 3. Meta-analysis on ASD and AD: Third-Trimester Exposure.

eFigure 4. Meta-analysis on ASD and AD: Prepregnancy Exposure.

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable. Description of the Studies on Antidepressant Exposure During Pregnancy and ASD

Study	-	Period	Population				Exclusion	Control	Exposure
	n			e size		criteria	criteria	group	
		01/01/199			Canad	Singletons	-	Infants not	At least 1
	t	8-	Children/	56	а	born		exposed in	prescription
2015			Pregnancy			between		utero to AD.	during
		9	Cohort.			98/01/01			pregnancy
						and			or a
						09/12/31,			prescription
						≥37weeks'			before
						gestation.			pregnancy
						Mothers			overlapping
						covered by			with the first
						the RAMQ			day of
						drug plan 12			gestation.
						months			
						minimum			
						before and			
						during			
						pregnancy.			
	Cohor			626		Singletons	Children with	Children of	SSRI use
al, 2013	t	2010	Medical	875	rk	born in	genetic	mothers	from 4
			Birth			Denmark	conditions:	without	weeks
			Registry;			between	fragile X	SSRI	before the
			Danish			96/01/01	syndrome,	prescription	beginning of
			National			and	tuberous		the
			Prescription			05/12/31;	sclerosis,	years before	pregnancy
			Registry;			with	Angelman's	pregnancy	until
			Danish				syndrome,	through	delivery.
			Psychiatric			age known.	Down's	delivery	
			Central				syndrome,		
			Register;				DiGeorge's		
			Danish Civil				syndrome,		
			Registration				neurofibromato		
			System				sis, Prader–		
							Willi syndrome;		
							Congenital		
							rubella		
							syndrome.		

Study	-	Period	Population			Inclusion	Exclusion	Control	Exposure
-	n			e size		criteria	criteria	group	
Sorense n et al, 2013	Cohor t	2010	Danish Medical Birth Registry; Danish National Prescription Registry; Danish Psychiatric Central Register; Danish Civil Registration System; Danish National Hospital Register	655 615	Denma rk	F84.8, F84.9. Time of conception after 96/02/01. Antidepress ant drugs with ATC	missing) values for gestational age (≤23 weeks and ≥45 weeks). Missing information about mothers. Adopted children. Children who died during the first year of life. Children who	Children of mothers without AD prescription s from 30 days before conception to delivery	Antidepress ant use from 30 days before conception to delivery
Castro et al, 2016	Case- contro I		Partners HealthCare system; the Beth Israel Deaconess Medical Center, the Boston Children's Hospital, Massachuse tts Registry of Vital Records and Statistics.	1245 cases – 3405 control s	United States	19 years.	Children with ASD not having a match in the control population.		menstrual

Study	Desig	Period	Population	Sampl	Countr	Inclusion	Exclusion	Control	Exposure
	n		_	e size	у	criteria	criteria	group	_
Clement s et al, 2015			The Partners HealthCare electronic health record: Massachuse tts General Hospital (MGH), Brigham and Women's Hospital (BWH), Newton- Wellesley Hospital (NWH), as well as from community and specialty hospitals which are part of the Partners HealthCare system, and affiliated outpatient clinics.		United States	Children aged of 2 – 19 years. One ICD-9 code of 299 (pervasive developmen tal disorder) between 1997 and 2010. Delivered at MGH, BWH, NWH.	Unconfirmable mother-child matches.	Non-ASD control children delivered at MGH, BWH, or NWH with the same year of birth, birth hospital, sex, insurance type as a proxy for socioecono mic status, race/ethnicit y, and preterm versus full- term status. No prior history of ASD, ADHD, or intellectual disability (ICD9 of 299, 314, or 317–319) Matched at a ratio of 3 controls per case.	Antidepress ant use at any time during pregnancy

Study	Desig n	Period				Inclusion criteria	Exclusion criteria	Control group	Exposure
Gidaya et al, 2014	Case- contro I	2011	Danish Drug Prescription Register; Danish Psychiatric Central Register; Danish Civil Registration System; Danish National Hospital Register	57 365	Denma rk	Children born in Denmark between 97/01/01 and 06/12/3. Singletons or one child randomly selected from multiple births. Subjects' records from 99/01/01 to 11/03/31 were searched for ICD-10 code F840,F841, F845, F848, and F849	Children not linked to biological mother. Mother not living in Denmark one year before delivery. Child's gestational age <23 weeks or >43 weeks.	Children from the Danish Civil Registration System without ASD admission diagnoses. 10 controls per case individually matched for birth month and year	SSRI use from 3 months prior to the estimated date of conception to delivery
Harringt on et al, 2014	Case- contro I		CHARGE Standardize d telephone interview	812	States	Children 2– 5 years old, born in California and at least one parent who speaks English or Spanish, diagnosed with ASD or other developmen t disorders. Living with at least one biological parent and in catchment area of specified California Regional Centers that coordinate services for those with developmen tal disabilities	Siblings of probands.	Children identified using state birth files Matched with autism cases for age, sex and regional center (targeted 4:1 male to female ratio).	SSRI use 3 months before conception to delivery.

 $\ensuremath{\mathbb{C}}$ 2017 American Medical Association. All rights reserved.

Study	Desig	Period	Population	Sampl	Countr	Inclusion	Exclusion	Control	Exposure
	n		-	e size		criteria	criteria	group	_
Rai et al, 2013	Case- contro I		Stockholm	47		All children 0–17 years	Missing maternal identification numbers. Adopted children. Living in Stockholm	Children in Stockholm Youth Cohort without ASD diagnosis. Matched for sex, birth month and birth year in a ratio of 1 case to 10 controls	SSRI use reported by mothers at their first antenatal interview.
Eriksson et al, 2012	Case- contro I		Autism	173 578	Swede n	Children born 2002 and 2006. Registered with a clinical	Non Swedish or English speaking families. Children who emigrated. Children referred to general rehabilitation centers due to complex needs in addition to ASD. Families who declined invitation.	Children born in Stockholm County between 2002–2006 without a clinical diagnosis of ASD.	Antidepress ant use during pregnancy.

Study	Desig Perio	d Population			Inclusion	Exclusion	Control	Exposure
	n		e size	у	criteria	criteria	group	
•	-	-			criteria Children born in KPNC facility between January	criteria Medical records contained an ASD diagnosis recorded after initial control selection		SSRI prescription for mothers in the year prior to delivery.

Legend: AD=Antidepressants ; ASD=Autism Spectrum Disorder ; SSRI=Selective Serotonin Reuptake Inhibitors

	log			OR or HR	OR or I	
Study or Subgroup	[OR or HR]	SE	Weight	Random, 95% C	Random, 9	95% Cl
Adjusted Odds Ratio						
Castro et al., 2016	0.09	0.42	7.4%	1.10 [0.48, 2.49]	-	-
Clements et al., 2015	0.61	0.25		1.84 [1.12, 3.02]		-
Croen et al., 2011	1.33	0.37		3.78 [1.82, 7.84]		
Gidaya et al., 2014	0.79	0.14	42.4%	2.20 [1.68, 2.87]		ł
Harrington et al., 2014	0.32	0.54	4.5%	1.38 [0.48, 4.01]		
Rai et al., 2013	0.82	0.25	18.4%	2.27 [1.40, 3.71]		F
Total (95% CI)			100.0%	2.09 [1.66, 2.64]		•
Heterogeneity: Tau ² = 0	0.01; Chi² = 5	.99, df	= 5 (P =	0.31); l² = 17%		
Test for overall effect: Z	2 = 6.23 (P <	0.000	01)			
Adjusted for past psy	chiatric diso	rders	Odds Ra	tio*		
Castro et al., 2016	-0.11	0.36	14.8%	0.89 [0.44, 1.81]		
Clements et al., 2015	0.35	0.26	20.9%	1.43 [0.85, 2.38]	┼┳╌	
Croen et al., 2011	0.64	0.26	21.3%	1.90 [1.15, 3.14]		_
Gidaya et al., 2014	0.72	0.13	31.9%	2.05 [1.58, 2.66]	1	F
Rai et al., 2013	1.41	0.45	11.1%	4.10 [1.71, 9.84]	-	
Total (95% CI)			100.0%	1.79 [1.27, 2.52]	•	•
Heterogeneity: Tau ² = 0).08; Chi² = 8	.82, df	= 4 (P =	0.07); l² = 55%		
Test for overall effect: Z	2 = 3.31 (P =	0.000	9)			
Adjusted for past psy	chiatric diso	rders	Hazard F	Ratio		
Boukhris et al., 2016	-0.17	0.25	42.9%	0.84 [0.52, 1.36]	-#-	
Hviid et al., 2013	0.30	0.17	57.1%	1.35 [0.97, 1.87]		
Total (95% CI)			100.0%	1.10 [0.70, 1.75]	•	
Heterogeneity: Tau ² = 0			f = 1 (P =	0.11); l² = 61%		
Test for overall effect: Z	2 = 0.41 (P =	0.68)				
				H		
				0.0		10 100
					Protectio	Risk

eFigure 1. Meta-analysis on ASD and AD: First-Trimester Exposure

* Adjusted for maternal depression, except for Rai et al. (any maternal psychiatric disorder)

eFigure 2. Meta-analysis on ASD and AD: Second-Trimester Exposure

				OR			OR		
Study or Subgroup	log[OR]	SE	Weight	Random, 95%	6 CI	Rando	m, 95%	CI	
Adjusted Odds Ratio									
Castro et al., 2016	0.33	0.40	10.7%	1.39 [0.63, 3.	03]		-		
Clements et al., 2015	0.59	0.26	24.9%	1.81 [1.08, 3.	02]				
Croen et al., 2011	0.65	0.54	5.8%	1.92 [0.66, 5.	57]			_	
Gidaya et al., 2014	0.88	0.18	54.7%	2.40 [1.70, 3.	39]				
Harrington et al., 2014	-0.12	0.66	3.9%	0.89 [0.24, 3.2	24]				
Total (95% CI)			100.0%	2.00 [1.55, 2.	59]				
Heterogeneity: Tau ² = 0).00; Chi² =	= 3.55	5, df = 4 (P = 0.47); I ² = 0)%				
Test for overall effect: Z	<u>′</u> = 5.30 (P	< 0.0	00001)						
Adjusted for past psy	chiatric di	isord	er Odds	Ratio					
Castro et al., 2016	0.09	0.38	19.4%	1.10 [0.53, 2.3	29]	-			
Clements et al., 2015	0.29	0.27	29.1%	1.34 [0.78, 2.1	28]		┼∎╌		
Croen et al., 2011	0.59	0.64	8.2%	1.80 [0.51, 6.	31]	-		_	
Gidaya et al., 2014	0.83	0.18	43.3%	2.30 [1.63, 3.	24]		-∎-		
Total (95% CI)			100.0%	1.67 [1.14, 2.4	45]		•		
Heterogeneity: Tau ² = 0).06; Chi² =	= 4.8	5, df = 3 (P = 0.18); I ² = 3	38%				
Test for overall effect: Z			•						
					0.01	0.1	1	10	100

eFigure 3. Meta-analysis on ASD and AD: Third-Trimester Exposure

				OR			OR				
Study or Subgroup	log[OR]	SE	Weight	Random, 95%	CI	Rando	om, 95%	CI			
Adjusted Odds Ratio											
Castro et al., 2016	0.18	0.38	19.5%	1.20 [0.57, 2.5	0]						
Clements et al., 2015	0.39	0.27	25.8%	1.48 [0.87, 2.5	1]		┼┳──				
Croen et al., 2011	1.06 (0.52	13.3%	2.87 [1.03, 8.0	2]						
Gidaya et al., 2014	1.13 (0.19	30.8%	3.10 [2.11, 4.5	3]						
Harrington et al., 2014	0.17 (0.62	10.5%	1.18 [0.35, 4.0	2]						
Total (95% CI)			100.0%	1.90 [1.20, 3.0	2]						
Heterogeneity: Tau ² = 0.14; Chi ² = 9.07, df = 4 (P = 0.06); l ² = 56%											
Test for overall effect: Z	= 2.72 (P	= 0.0	006)								
Adjusted for past psyc	chiatric dis	sord	er Odds	Ratio							
Castro et al., 2016	-0.16 (0.38	24.2%	0.85 [0.41, 1.8	0]	-					
Clements et al., 2015	0.07 (0.29	28.3%	1.08 [0.61, 1.8	9]						
Croen et al., 2011	0.87 (0.62	15.6%	2.39 [0.72, 7.9	7]		╶┼─┲─				
Gidaya et al., 2014	0.99 (0.20	31.9%	2.69 [1.81, 4.0	1]						
Total (95% CI)			100.0%	1.54 [0.82, 2.9	0]						
Heterogeneity: Tau ² = 0	.28; Chi² =	11.1	15, df = 3	(P = 0.01); I ² = 7	73%						
Test for overall effect: Z											
				F O	.01	0.1	1	10	100		
				0		otection	•	Risk	100		

eFigure 4. Meta-analysis on ASD and AD: Prepregnancy Exposure

